{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:41:49Z","timestamp":1792082509126,"version":"4.4.0"},"reference-count":95,"publisher":"Wiley","issue":"s426","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":1257,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p><jats:bold>Objective:\u2002<\/jats:bold> To assess the potential role of atypical antipsychotics as mood stabilizers.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold> A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long\u2010term therapy the atypical antipsychotics do have clinically significant side\u2010effects of which clinicians need to be aware.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.<\/jats:p>","DOI":"10.1111\/j.1600-0447.2005.00524.x","type":"journal-article","created":{"date-parts":[[2005,4,11]],"date-time":"2005-04-11T17:49:21Z","timestamp":1113241761000},"page":"29-38","source":"Crossref","is-referenced-by-count":22,"title":["Atypical mood stabilizers: a \u2018typical\u2019 role for atypical antipsychotics"],"prefix":"10.1111","volume":"111","author":[{"given":"G. S.","family":"Malhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ivanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. B.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2004.tb06238.x"},{"key":"e_1_2_8_3_2","volume-title":"Manic\u2010depressive illness","author":"Goodwin F","year":"1990"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404901204"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70093-9"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1614.2004.01557.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00137.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317010-00002"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.53.082901.103933"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00410.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-2406.2003.00060.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group","volume":"156","author":"Tohen M","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000085410.08426.9a"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.12.1218"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200209000-00003"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199911000-00003"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1011"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"e_1_2_8_21_2","unstructured":"SachsG SanchezR MarcusRet\u00a0al.Aripiprazole versus placebo in acute mania: results from a second study. 55th Meeting of the Institute of Psychiatric Services. Boston MA USA 2003."},{"issue":"1","key":"e_1_2_8_22_2","first-page":"39","article-title":"Aripiprazole in acute mania: results from a second placebo\u2010controlled study","volume":"6","author":"Hadjakis W","year":"2004","journal-title":"Bipolar Disord"},{"key":"e_1_2_8_23_2","unstructured":"BourinM AubyP SwaninkRet\u00a0al.Aripiprazole versus haloperidol for maintained treatment effect in acute mania. Annual Meeting of the American Psychiatric Association May 17\u201322 2003. San Francisco USA 2003."},{"issue":"1","key":"e_1_2_8_24_2","first-page":"35","article-title":"Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1)","volume":"5","author":"Brecher M","year":"2003","journal-title":"Bipolar Disord"},{"issue":"1","key":"e_1_2_8_25_2","first-page":"35","article-title":"Quetiapine vs. placebo for acute mania associated with bipolar disorder (STAMP 1)","volume":"5","author":"Brecher M","year":"2003","journal-title":"Bipolar Disord"},{"issue":"1","key":"e_1_2_8_26_2","first-page":"57","article-title":"Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2)","volume":"5","author":"Jones M","year":"2003","journal-title":"Bipolar Disord"},{"key":"e_1_2_8_27_2","unstructured":"JonesM HuizarK.Quetiapine as monotherapy for mania associated with bipolar disorder. 43rd Annual NCDEU Conference. Boca Raton FL USA 2003:158."},{"issue":"1","key":"e_1_2_8_28_2","first-page":"70","article-title":"Quetiapine in combination with mood stabilizers for the treatment of acute mania associated with bipolar disorder","volume":"5","author":"Mullen J","year":"2003","journal-title":"Bipolar Disord"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00115.x"},{"issue":"1","key":"e_1_2_8_30_2","first-page":"s330","article-title":"Quetiapine in combination with mood stabiliser for the treatment of acute mania associated with bipolar disorder","volume":"7","author":"Yatham LN","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"issue":"1","key":"e_1_2_8_32_2","first-page":"s327","article-title":"Adjunctive ziprasidone for bipolar mania: short and long\u2010term data","volume":"7","author":"Weisler R","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_33_2","unstructured":"HirschfeldR KeckPE KarcherK KramerM GrossmanF.Rapid antimanic effect of risperidone monotherapy: a three\u2010week multicenter randomized double\u2010blind placebo\u2010controlled trial. American Psychiatric Association Annual Meeting May 17\u201322 2003. San Francisco CA USA 2003."},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)92033-5"},{"key":"e_1_2_8_35_2","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double\u2010blind randomized controlled trial","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.556"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00481-5"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200307000-00005"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199703000-00006"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.12.2.283"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200108000-00006"},{"issue":"1","key":"e_1_2_8_44_2","first-page":"s327","article-title":"IM ziprasidone in agitated psychotic patients with bipolar diagnoses","volume":"7","author":"Daniel DG","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1079"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1211"},{"key":"e_1_2_8_48_2","unstructured":"MilevRV AbrahamG VoutsilakosF HoakenP.Open\u2010label add\u2010on quetiapine for bipolar depression: an eight\u2010week trial. American Psychiatric Association Annual Meeting May 1\u20136 2004. New York NY USA 2004."},{"key":"e_1_2_8_49_2","unstructured":"CalabreseJ MacfaddenW MccoyR MinkwitzM WilsonE MullenJ.Double\u2010blind placebo\u2010controlled study of quetiapine in bipolar depression. American Psychiatric Association 2004 Annual Meeting\u2010Abstracts on Disk. 157th Annual Meeting of American Psychiatric Association American Psychiatric Association New York NY USA 2004."},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2001.00932.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00435-9"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.174.5.460b"},{"issue":"1","key":"e_1_2_8_53_2","first-page":"89","article-title":"Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double\u2010blind, placebo\u2010controlled 12\u2010month clinical trial","volume":"5","author":"Tohen M","year":"2003","journal-title":"Bipolar Disord"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1011"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01204.x"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00334-8"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.982"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0502"},{"key":"e_1_2_8_59_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1176\/ajp.156.8.1164","article-title":"Clinical outcome in a randomized 1\u2010year trial of clozapine versus treatment as usual for patients with treatment\u2010resistant illness and a history of mania","volume":"156","author":"Suppes T","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199804000-00012"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00002-0"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n07a02"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.3109\/10401239909147062"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0104"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1263"},{"issue":"1","key":"e_1_2_8_66_2","first-page":"89","article-title":"Olanzapine vs. lithium in relapse prevention in bipolar disorder: a randomized double\u2010blind controlled 12\u2010month clinical trial","volume":"5","author":"Tohen M","year":"2003","journal-title":"Bipolar Disord"},{"issue":"1","key":"e_1_2_8_67_2","first-page":"89","article-title":"Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double\u2010blind, placebo\u2010controlled 12\u2010month clinical trial","volume":"5","author":"Tohen M","year":"2003","journal-title":"Bipolar Disord"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.4.337"},{"issue":"1","key":"e_1_2_8_69_2","first-page":"s161","article-title":"Aripiprazole for relapse prevention in bipolar disorder: a 26\u2010week placebo controlled study","volume":"7","author":"Mcquade RD","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0907"},{"issue":"21","key":"e_1_2_8_71_2","first-page":"16","article-title":"Weight gain associated with use of psychotropic medications","volume":"60","author":"Sachs G","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0506"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2003.00169.x"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000085403.08426.f4"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0410"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n1109"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0509"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000085404.08426.3a"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.2.290"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.11.1021"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.8.1037.32876"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.12.1773"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0911"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020464017021"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)89080-3"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1205"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.6.1033"},{"key":"e_1_2_8_89_2","first-page":"66","article-title":"Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations","volume":"35","author":"Kelly D","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"e_1_2_8_91_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.4.483"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2247"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.3109\/10401230309085668"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1614.2005.01571.x"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00413.x"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00411.x"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.2005.00524.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.2005.00524.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T19:47:19Z","timestamp":1695757639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.2005.00524.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":95,"journal-issue":{"issue":"s426","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1600-0447.2005.00524.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.2005.00524.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}